Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 148.00 | |
5 mg | In stock | $ 278.00 | |
10 mg | In stock | $ 455.00 | |
25 mg | In stock | $ 647.00 | |
50 mg | In stock | $ 913.00 | |
100 mg | In stock | $ 1,390.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 313.00 |
Description | AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL). |
Targets&IC50 | CLK1:50 nM, CLK2:5 nM, IRAK4:5 nM, CLK4:8 nM, Haspin:4 nM, IRAK1:23 nM |
Molecular Weight | 385.5 |
Formula | C21H31N5O2 |
CAS No. | 2196204-23-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (25.94 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
AZ1495 2196204-23-4 Cell Cycle/Checkpoint Immunology/Inflammation NF-Κb IRAK CDK Haspin Kinase Interleukin-1 receptor associated kinase interleukin-1 receptor associated kinase 4 (IRAK4) inhibit AZ 1495 cancer IL-1R associated kinase weak base diffuse large B-cell lymphoma (DLBCL) Inhibitor interleukin-1 receptor associated kinase 1 (IRAK1) AZ-1495 inhibitor